D
Range Impact, Inc. RNGE
$0.1623 $0.01238.20%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
D
Sell 11/21/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D- from D+ on 11/21/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0121 to -$0.0517, net income declined 301.43% from -$1.23M to -$4.92M, and total capital declined 46.34% from $17.2M to $9.23M.
D
Sell 10/7/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 10/7/2024 due to a decline in the volatility index and total return index.
C
Hold 8/19/2024Upgraded
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 8/19/2024 due to a major increase in the efficiency index, growth index and solvency index. Operating cash flow increased 50.54% from -$1.11M to -$550.5, and debt to equity declined from 1.13 to 1.1.
D
Sell 4/11/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 4/11/2024 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 143.18% from $1.47M to -$636.1, net income declined 102.44% from $3.4M to -$83, and earnings per share declined from $0.0408 to -$0.0009.
C
Hold 12/20/2023Upgraded
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 12/20/2023 due to an increase in the total return index and volatility index.
D
Sell 12/5/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D+ from C- on 12/5/2023 due to a decline in the total return index.
C
Hold 11/20/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to C- from D- on 11/20/2023 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 9,150.54% from $36.8 to $3.4M, and total capital increased 100.39% from $8.94M to $17.92M.
D
Sell 9/1/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 9/1/2023 due to an increase in the volatility index and total return index.
E
Sell 8/17/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 8/17/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell 8/2/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 8/2/2023 due to a significant increase in the growth index, volatility index and valuation index. EBIT increased 155.57% from -$183.2 to $101.8, earnings per share increased from -$0.0029 to $0.0005, and total revenue increased 32.62% from $3.01M to $4M.
E
Sell 7/24/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index and total return index.
D
Sell 7/5/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 7/5/2023 due to an increase in the volatility index and valuation index.
E
Sell 6/20/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 6/20/2023 due to a substantial decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0008 to -$0.0029, and EBIT declined 225.98% from -$56.2 to -$183.2.
D
Sell 3/14/2023Downgrade
Range Impact, Inc. (RNGE) was downgraded to D- from D on 03/14/2023.
D
Sell 2/23/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell 2/8/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and total return index.
D
Sell 5/31/2022Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell 5/13/2022Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 5/13/2022 due to a major decline in the solvency index, growth index and total return index. The quick ratio declined from 0.37 to 0.05, and operating cash flow declined 2.92% from -$383 to -$394.2.
D
Sell 5/5/2022Upgraded
Range Impact, Inc. (RNGE) was upgraded to D from D- on 05/05/2022.
D
Sell 4/20/2022Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 4/20/2022 due to a major decline in the solvency index and total return index. The quick ratio declined from 9.61 to 0.37.
D
Sell 11/9/2021Upgraded
Range Impact, Inc. (RNGE) was upgraded to D from E+ on 11/09/2021.
E
Sell 11/8/2021Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0071 to -$0.0121, and operating cash flow declined 0.97% from -$557.3 to -$562.7.
D
Sell 8/6/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 8/6/2020 due to an increase in the volatility index and total return index.
D
Sell 7/22/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/22/2020 due to a decline in the valuation index and volatility index.
D
Sell 7/1/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 7/1/2020 due to an increase in the volatility index.
D
Sell 6/30/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 6/30/2020 due to a major increase in the growth index, volatility index and total return index. Operating cash flow increased 12.44% from -$835.1 to -$731.2, earnings per share increased from -$0.0156 to -$0.0148, and EBIT increased 2% from -$748.8 to -$733.8.
E
Sell 5/13/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 5/13/2020 due to a noticeable decline in the efficiency index and volatility index.
D
Sell 4/28/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 4/28/2020 due to an increase in the volatility index.
E
Sell 4/13/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 4/13/2020 due to a decline in the volatility index.
D
Sell 3/23/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index.
E
Sell 3/6/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 3/6/2020 due to a decline in the volatility index.
D
Sell 2/18/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 2/18/2020 due to an increase in the growth index. Earnings per share increased from -$0.0235 to -$0.0156, and EBIT increased 26.69% from -$1.02M to -$748.8.
E
Sell 2/4/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 2/4/2020 due to a decline in the growth index and volatility index.
D
Sell 1/10/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 1/10/2020 due to an increase in the growth index and volatility index.
E
Sell 12/26/2019Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 12/26/2019 due to a large decline in the solvency index, growth index and volatility index. Debt to equity increased from 0.03 to 0.05, and the quick ratio declined from 4.08 to 2.51.
D
Sell 7/16/2019Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/16/2019 due to a significant decline in the total return index, efficiency index and volatility index. Net income declined 690.75% from -$1.21M to -$9.56M, and total capital declined 68.36% from $15.87M to $5.02M.
D
Sell 11/15/2018Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/15/2018 due to a significant decline in the efficiency index and solvency index. Net income declined 7.54% from -$1.14M to -$1.22M.
C
Hold 8/16/2018Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 8/16/2018 due to a significant increase in the efficiency index, solvency index and valuation index.
D
Sell 11/16/2017Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from D+ on 11/16/2017 due to a significant decline in the efficiency index, valuation index and volatility index.
D
Sell 8/11/2017Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 8/11/2017 due to a significant increase in the efficiency index, valuation index and solvency index. Net income increased 0.69% from -$1.11M to -$1.11M.
D
Sell 6/29/2017Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 6/29/2017 due to a significant decline in the efficiency index, valuation index and growth index. Operating cash flow declined 64.4% from -$304.8 to -$501.1, EBIT declined 47.76% from -$912.1 to -$1.35M, and total revenue declined 20.91% from $39.7 to $31.4.
C
Hold 2/16/2017Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 2/16/2017 due to a significant increase in the efficiency index, total return index and volatility index. Total capital increased 26% from -$920.5 to -$681.2.
D
Sell 11/18/2016Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/18/2016 due to a significant decline in the efficiency index, growth index and solvency index. Net income declined 160.92% from -$439.4 to -$1.15M, earnings per share declined from -$0.0436 to -$0.0936, and EBIT declined 93.11% from -$423.8 to -$818.4.
C
Hold 10/19/2016Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D+ on 10/19/2016 due to an increase in the total return index and volatility index.
D
Sell 9/21/2016Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 9/21/2016 due to an increase in the total return index, valuation index and growth index. Earnings per share increased from -$0.1187 to -$0.0436, and EBIT increased 14.37% from -$494.9 to -$423.8.
D
Sell 7/1/2016Upgraded
Stevia First Corporation (STVF) was upgraded to D from E+ on 7/1/2016 due to a significant increase in the efficiency index, solvency index and growth index.
E
Sell 6/24/2016Downgrade
Stevia First Corporation (STVF) was downgraded to E+ from D on 6/24/2016 due to a significant decline in the solvency index, growth index and efficiency index.
D
Sell 3/11/2016Downgrade
Stevia First Corporation (STVF) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
D
Sell 1/15/2016Downgrade
Stevia First Corporation (STVF) was downgraded to D+ from C- on 1/15/2016 due to a large decline in the total return index.
C
Hold 12/31/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D+ on 12/31/2015 due to a large increase in the total return index and valuation index.
D
Sell 11/18/2015Downgrade
Stevia First Corporation (STVF) was downgraded to D+ from C- on 11/18/2015 due to a significant decline in the efficiency index, solvency index and valuation index. Total capital declined 74.17% from -$895.8 to -$231.4.
C
Hold 8/17/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 8/17/2015 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.29 to 0.58, and total revenue increased 6.91% from $57.9 to $61.9.
D
Sell 6/26/2015Downgrade
Stevia First Corporation (STVF) was downgraded to D from C- on 6/26/2015 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 0.67 to 0.29, and net income declined 26.21% from -$1.14M to -$842.7.
C
Hold 2/18/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 2/18/2015 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 40.95% from -$518.4 to -$730.7.
D
Sell 8/15/2014Downgrade
Stevia First Corporation (STVF) was downgraded to D from C- on 8/15/2014 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0223 to -$0.01, net income declined 54.04% from -$1.43M to -$655.8, and the quick ratio declined from 0.91 to 0.58.
C
Hold 7/1/2014Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 7/1/2014 due to a significant increase in the efficiency index, valuation index and solvency index. Debt to equity declined from 2.15 to 0, and net income increased 36.54% from -$1.05M to -$1.43M.
Weiss Ratings